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Rapid mineralization of cultured osteoblasts 
could be a useful characteristic in stem-cell 
mediated therapies for fracture and other 
orthopaedic problems. Dimethyl sulfoxide 
(DMSO) is a small amphipathic solvent 
molecule capable of simulating cell 
differentiation. We report that, in primary 
human osteoblasts, DMSO dose-dependently 
enhanced the expression of osteoblast 
differentiation markers alkaline phosphatase 
(ALP) activity and extracellular matrix 
mineralization. Furthermore, similar DMSO 
mediated mineralization enhancement was 
observed in primary osteoblast-like cells 
differentiated from mouse mesenchymal cells 
derived from fat, a promising source of 
starter cells for cell-based therapy. Using a 
convenient mouse pre-osteoblast model cell 
line MC3T3-E1 we further investigated this 
phenomenon showing that numerous 
osteoblast-expressed genes were elevated in 
response to DMSO treatment and correlated 
with enhanced mineralization. Myocyte 
enhancer factor 2c (Mef2c) was identified as 
the transcription factor most induced by 
DMSO, among numerous DMSO-induced 
genes, suggesting a role for Mef2c in 
osteoblast gene regulation. 
Immunohistochemistry confirmed expression 
of Mef2c in osteoblast-like cells in mouse 
mandible, cortical and trabecular bone. 
shRNAi-mediated Mef2c gene silencing 
resulted in defective osteoblast differentiation, 
decreased ALP activity and matrix 
mineralization and knockdown of osteoblast 
specific gene expression, including osteocalcin 
and bone sialoprotein. Flow on knockdown of 
bone specific transcription factors, Runx2 
and osterix by shRNAi knockdown of Mef2c 
suggests that Mef2c lies upstream of these two 
important factors in the cascade of gene 
expression in osteoblasts.  
 
INTRODUCTION 
 
 Skeletal patterning and subsequent 
cellular differentiation during development is a 
complex process involving the activation and 
suppression of gene regulatory programs leading 
to bone formation (1). Once fully developed, 
bone remains a dynamic tissue by undergoing 
continual remodelling which functions to repair 
microarchitectural defects and maintain skeletal 
integrity (2). Numerous cell types are involved 
in the formation and homeostasis of the skeleton. 
Amongst these are osteoblasts (bone-forming 
cells) which differentiate from committed 
mesenchymal osteoprogenitor cells (1). The 
differentiation of osteoblasts is a highly 
coordinated process involving a clearly defined 
temporal sequence of events characterised by the 
commitment, proliferation and subsequent 
maturation of precursor cells into terminally 
differentiated osteoblasts (3,4). During this 
process, early differentiating cells undergo 
proliferation and secrete a collagen type 1-rich 
extracellular matrix. In the next phase, cellular 
proliferation decreases and the cells express 
factors involved in matrix maturation such as 
alkaline phosphatase. In the final stage, 
osteoblasts initiate matrix mineralization and 
express factors such as integrin binding 
sialoprotein and osteocalcin (3-5).  
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 Osteoblast differentiation is tightly 
coordinated by the activities of transcriptional 
regulators; these include the master transcription 
factors RUNX2 and osterix (OSX) which govern 
the expression of genes involved in the 
developmental process (6). RUNX2 is 
indispensable for skeletal development and 
controls osteoblast differentiation by regulating 
the commitment of osteoprogenitors and 
activating major bone matrix genes (7). Osterix 
is also necessary for osteoblast differentiation 
and bone formation and functions downstream 
of RUNX2 (6). Other transcription factors with 
roles in osteoblasts include MSX2, DLX5, 
TWIST-1, AP1, ATF4, HOXA10 and ZFP521 
(6-9).  
 Dimethyl sulfoxide (DMSO; (CH3)2SO) 
is a small, amphipathic molecule that is widely 
used as a solvent due to its abilities to dissolve 
both polar and non-polar compounds (10). 
Currently, DMSO is used as a cryo-preserving 
agent in cell banking (11) commonly at 10% 
concentrations that are then injected directly into 
the patient. Notably, DMSO is reported to 
stimulate osteoblast differentiation in MC3T3-
E1, a mouse pre-osteoblast cell line, through 
ERK activation of transcription factors Runx2 
and osterix (12). 
 In this study, we show that DMSO acts 
as a potent enhancer of human and mouse 
osteoblast differentiation as demonstrated by the 
significant gains in alkaline phosphatase (ALP) 
activity and mineralization observed throughout 
differentiation. Significantly, the effects of 
DMSO were anabolic in nature, such that the 
extent of matrix mineralization in DMSO-treated 
cells was greater than that of non-treated control 
cells, even when experiments were continued to 
the point where all cells were terminally 
differentiated. DMSO-enhanced osteoblast 
differentiation was used, in the model cell line 
MC3T3-E1, to identify novel genes involved in 
the developmental process. Unexpectedly, Mef2c 
was the transcription factor most potently 
induced by DMSO. Mef2c is a MADS-box 
transcription factor that is most commonly 
associated with the development and 
differentiation of the heart and skeletal muscle 
(13). Here, we show that Mef2c gene expression 
is dynamically regulated during osteoblast 
differentiation and that shRNA-mediated Mef2c 
gene silencing is associated with highly 
significant decreases in ALP activity, osteoblast 
gene expression and matrix mineralization, 
demonstrating a critical role for Mef2c in 
osteoblast differentiation. 
 
MATERIALS AND METHODS 
 
Cell culture and osteoblast differentiation - 
MC3T3-E1 cells (sub clone 14) were maintained 
in Minimum Essential Medium (α-MEM) 
(Invitrogen) containing 10% fetal bovine serum 
(FBS, Invitrogen), 1% penicillin/streptomycin 
solution (Invitrogen) and 1 mM sodium pyruvate 
(Invitrogen): this medium augmented with 50 
µg/ml ascorbic acid and 10 mM beta-
glycerophosphate was termed osteogenic 
medium (OM). For osteoblast differentiation, 
cells were seeded in 24-well culture plates at a 
density of 2.5 x 104 cells/well in a total volume 
of 0.5 ml of medium, then at 48 hours medium 
was replaced with OM with various 
concentrations of DMSO. Medium was changed 
every 72 hours unless stated otherwise. For 
calvarial osteoblast differentiation, calvaria 
obtained from new born mice were rinsed in 
phosphate buffered saline (PBS) and digested 
four times sequentially with 0.1% Collagenase A 
and 0.2% Dispase II (Roche) in PBS to liberate 
embedded cells. The pooled digestion solution 
was passed through a 70 µm cell strainer and 
cells were recovered via centrifugation. The cells 
were seeded into culture flasks containing α-
MEM and grown for 3-4 days prior to osteoblast 
differentiation. Calvarial cells were prepared for 
osteoblast differentiation as per MC3T3-E1 cells. 
Human primary osteoblasts were obtained from 
biopsy material donated at orthopaedic 
procedures: bone was minced and washed in 
PBS, removing marrow and adipocytes and then 
treated with trypsin (Invitrogen) for 5 minutes. 
Pieces were then washed in PBS and osteoblasts 
permitted to grow out from explants in -MEM 
with 10% FBS (Invitrogen). Mineralization and 
ALP assays were done as for MC3T3-E1 cells. 
Adipocyte derived mesenchymal cells were 
obtained from two hour collagenase digestion at 
37ºC of excised, minced fat pads. Cells were 
washed in PBS and cultured in Dulbecco's 
Modified Eagle Medium (DMEM) with 5% FBS. 
293T cells were maintained in DMEM 
containing 10% FBS (Invitrogen) and 1% 
penicillin-streptomycin solution (Invitrogen). All 
cells were maintained at 37ºC in a humidified 
atmosphere with 5% CO2. DMSO concentrations 
are presented as percent volume. Procedures 
involving human samples were approved by the 
Queensland University of Technology 
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institutional committee. Procedures involving 
mice were approved by the animal ethics 
committee of Griffith University.  
Alkaline phosphatase activity and matrix 
mineralization assays - ALP activity was 
assessed via the spectrophotometric quantitation 
of p-nitrophenol generated through the 
hydrolysis of p-nitrophenyl phosphate (pNPP). 
Briefly, cells were washed with one volume of 
PBS and lysed with the addition of 200 µl 
50mM Tris-HCl, pH 8.0 and 0.5% Triton X-100 
(per well, 24-well plate). 10 µl of cell lysate was 
incubated with 200 µl of 1 M diethanolamine, 
0.5 mM MgCl2, pH 9.8 containing 10 mM pNPP 
for 15-30 min. The reaction was stopped by the 
addition of 50 µl 3M NaOH and the absorbance 
was measured at 405 nm. Enzyme activity was 
standardized using purified calf intestinal ALP 
(NEB) and normalised to protein content as 
measured by the DC protein assay kit (Bio-Rad). 
ALP activity was expressed as nanomoles of 
pNPP converted per min per mg protein 
(nmole/min/mg protein). Matrix mineralization 
was assessed using Alizarin Red S staining 
according to Gregory et al. (14). Units are 
absorbance of solubilised Alizarin Red S 
measured at 405 nM per culture well. One A405 
unit represents 2.96Mol Alizarin Red S 
precipitated per culture. 
RNA extraction and cDNA synthesis - 
RNA was extracted from cells using the acid 
guanidinium thiocyanate-phenol-chloroform 
method (15). For cDNA synthesis, 
approximately 1 µg of total RNA was treated 
with DNAse I (Sigma) to remove any residual 
DNA and converted to cDNA using the ImProm-
II reverse transcription system (Promega) 
according to the manufacturer’s instructions. 
Reactions were carried out in 20 µl volumes and 
all cDNA samples were diluted 1:5 in DNAse-
free water prior to real-time PCR.  
Primers and quantitative PCR (qPCR) - 
PCR primers used in the study are listed in Table 
1 and were designed from DNA sequences 
available through the Entrez Nucleotide database. 
Mouse gene nomenclature conventions are used 
(protein indicated by non-italics and  gene names 
in italics). The specificities of candidate primer 
pairs were assessed by BLAST (www.ncbi.org) 
and BLAT analyses (genome.ucsd.edu). Primer 
pairs were selected that gave single 
amplification products using in silico PCR 
(genome.ucsd.edu). Specificity of amplification 
was verified by acrylamide gel electrophoresis, 
revealing a single fragment of the predicted size. 
qPCR amplifications were performed in an 
iCycler iQ Real-Time PCR Detection System 
(Bio-Rad) using the iQ SYBR green supermix 
(Bio-Rad). Reactions were carried out in total 
volumes of 20 µl and included 250 nM of each 
primer and 2 µl of diluted cDNA template 
containing 100 ng cDNA. The thermal cycler 
conditions were as follows: Step 1, 95 ºC for 
2:30 min; Step 2, 95 ºC for 10 s, 59 ºC for 10 s 
and 72 ºC for 25 s (45 cycles); step 3, melt curve 
analysis from 59-95 ºC in 0.5 ºC increments. The 
specificity of the individual amplifications was 
assessed by the examination of the melt curves 
to confirm the presence of single gene-specific 
peaks of the characteristic melting temperature. 
Gene expression levels were normalised to the 
normalisation factor generated by the average of 
Actb, B2m, Hmbs and Hprt1 internal control 
genes as determined by the GeNorm algorithm 
of Vandesomple et al. (16). Transcript levels are 
presented as fold change compared to zero time 
baseline levels.  
 Microarray analysis - Affymetrix and 
Illumina genechip microarray analysis was 
conducted at the Australian Genome Research 
Facility, Melbourne, Australia. For each sample, 
total RNA (10µg) underwent quality assessment 
by running a sample through an Agilent 
bioanalyzer prior to microarray processing and 
scanning.  
 Immunohistochemistry - C57BL/6J mice 
were either day 15 fetal or week 12 adult. 
Tissues were fixed in 4% paraformaldehyde/PBS, 
decalcified in 0.5M EDTA for 2 weeks, and 
embedded in paraffin. Five-micrometer sections 
were prepared for immunohistochemistry. Slides 
were blocked with 1% FBS for 10 minutes, then 
incubated for 2 hours at 21ºC with rabbit 
antiMEF2C primary antibody (Abcam, 64644) 
diluted 1:100 in buffered saline at a final 
concentration of 9 μg/ml, or with a nonimmune 
rabbit IgG (Santa Cruz Biotechnology) using the 
same final concentration, followed by rinses and 
addition of a biotinylated goat anti-rabbit IgG 
(Santa Cruz Biotechnology) for 30 min at room 
temperature. After incubation with streptavidin-
horseradish peroxidase (DAKO) for 30 min at 
room temperature, slides were stained by 
exposure to DAB-liquid chromogen (DAKO) 
followed by counterstaining with Mayer’s 
hematoxylin and mounted in Cytoseal 60 
(Richard Allan Scientific). Positive antibody 
staining was identified by the presence of brown 
color. 
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shRNA constructs, retroviral particle 
production and infection - Mef2c shRNA 
sequence 1 (Sh1) was previously described (17). 
Sh2 and sh3 were designed using the Promega 
siRNA Target Designer (Version 1.51) in the 
mouse Mef2c mRNA. Sequence specificities 
were assessed via BLAST analysis. Forward and 
reverse oligonucleotides encoding the shRNA 
sequences (Table 1) were annealed via thermal 
cycling and cloned into the BamHI and EcoRI 
sites of pSIREN-RetroQ (Clontech). The 
pSIREN-RetroQ Luc vector (Clontech) which 
targets firefly luciferase was used as a control. 
Retroviral particle production was performed by 
co-transfection of pSIREN-RetroQ vectors, the 
VSV-G envelope glycoprotein vector pCSIG and 
the Friend MLV-based Gag-Pol expression 
vector pC57GP (18) in 293T cells using Fugene 
HD transfection reagent. Fresh medium was 
added to cells 24 hours post-transfection and 
viral supernatants were harvested a further 48 
hours later. Viral supernatants were passed 
through a 0.45 µm pore size filter and used 
directly for infections. Infections were 
performed by seeding MC3T3-E1 cells at 2.5 x 
105 cells in 25 cm2 culture vessels. 24 hours later, 
the medium was replaced with viral supernatant 
containing 8 µg/ml polybrene. A further 24 
hours later, infected cells were selected by 
replacing the viral supernatant with fresh 
medium containing 4 µg/ml puromycin. Infected 
cells were expanded in culture prior to use for 
subsequent analyses. Transient transfections 
were done using FuGene (Roche) according to 
the manufacturer’s protocol. Mef2c expression 
vector was constructed in pBABE vector 
(Addgene) using mouse Mef2c coding region 
amplified from MC3T3-E1 cDNA. pOSLUC 
was made by inserting the 600base pairs of 
human osteocalcin promoter upstream of firefly 
luciferase in the pGLBasic vector (Promega). 
This construct contain Runx2, osterix and 
vitamin D receptor binding sites. Renilla 
luciferase was used as a control for transfection 
efficiency according to the Dual-Glo procedure 
(Promega). Phosphorylation status of kinases 
was assayed using RayBio Phospho-ELISA kits 
exactly according to the manufacturer’s 
instructions. 
 Cellular proliferation assays - Cellular 
proliferation was assessed using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) method. MC3T3-E1 cells were 
seeded at 1 x 104 cells per well in 24-well 
culture plates and grown in osteogenic medium 
for 1 to 7 days. Cultures were gently washed 
once with warm PBS and fresh medium 
containing MTT to a final concentration of 0.5 
mg/ml was added to the wells. After an 
incubation period of three hours, medium was 
removed and the dye solubilised via the addition 
of 200 µl of isopropanol containing 0.1 % 
sodium dodecyl sulfate and 0.04 N hydrochloric 
acid. The absorbance of the dye solution was 
measured at 570 nm. 
 Statistical analysis - ALP activity, ECM 
mineralization and cellular proliferation assays 
were assessed using Student’s t-test or analysis 
of variance with LSD post-hoc tests. Analysis of 
variance of natural-log transformed gene 
expression data with LSD post-hoc tests was 
used to assess the significance of differences 
betweens means. For time course analysis the 
generalized linear model (GLM, SPSS) was used. 
Cycle threshold corrected for housekeeper genes 
was considered a normally distributed trait and 
used for statistical analysis. Significant 
differences were denoted by p<0.01. Error bars 
in graphs represent a standard error.  In some 
cases where effects are obvious and substantial, 
p values are not presented. 
 
RESULTS 
 
DMSO promotes osteoblast differentiation –
Primary human osteoblasts were cultured in OM 
supplemented with increasing concentration of 
DMSO, resulting in increased ALP activity (Fig. 
1A) and enhanced mineral formation as detected 
using Alizarin red staining (Fig. 1B). Similarly, 
mouse mesenchymal cells derived from 
testicular fat pad cultured in OM, exhibited a 
similar dose response of increased ALP activity 
enhanced mineralization to DMSO 
supplementation (Fig. 1C and D, respectively). 
The response of the pre-osteoblast 
model cell line, MC3T3-E1, to DMSO was 
characterised in detail for dose response of ALP 
activity and mineralization (at 12 days, Fig. 2A 
and 2B, respectively) and time course of 
response at 0.55% DMSO (Fig. 2C and 2D, 
respectively). Enzyme activity levels were 
maximally induced (2.9-fold) at 0.55% DMSO 
and gradually decreased at the two higher doses 
of 0.8 and 1.0%, although still significantly 
elevated compared to control. In parallel, a 
highly significant dose-dependent increase in 
ECM mineralization was also observed in 
response to DMSO treatment (Fig. 2B). The rise 
in mineralization paralleled ALP activity. As 
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expected, mineralization was not detected over 
the first five days of differentiation for either 
treatment group. By seven days, small amounts 
of mineralization were detectable in both groups 
with levels slightly greater in DMSO-treated 
cells. Beyond that time, DMSO-treated cells 
contained significantly more mineral than 
control cells at every time point and culminated 
in a 2.4-fold increase by day 21. These data 
indicated that DMSO exerted an anabolic effect 
on MC3T3-E1 osteoblast differentiation where 
cells contained significantly increased levels of 
ALP enzyme activity and deposited greater 
amounts of mineral in response to treatment.  
Exposure of cells in OM to DMSO for 
the first three days of culture was sufficient for 
the maximal enhanced mineralization effect, as 
delayed addition did not result in increased 
mineralization (Fig. 2E). These data suggest a 
critical early time window of effect of DMSO on 
MC3T3-E1 cells. In the first two days DMSO 
did not have a significant effect on cellular 
proliferation; however, a minor suppression 
became apparent at three days that persisted as 
cells differentiated under the effect of DMSO 
and OM (Fig. 2F). 
A critical early window of exposure to 
DMSO was observed, although the full 
mineralization effect in MC3T3-E1 cells 
developed over several days after this critical 
window. If DMSO had a direct inducing effect 
on bone specific promoters, increased gene 
induction might be expected within that 72 hour 
window. This was tested by transfecting a 
human osteocalcin promoter-luciferase construct 
into MC3T3-E1 cells, and culturing in OM for 
48 hours. DMSO (2.5%) exposure was limited to 
the last 24 hours prior to harvest (at 72 hours 
after transfection) and assay in order minimise 
effects on proliferation and focus on 
transcription effects. Two known inducers of 
human osteocalcin, 1,25dihydroxyvitamin D3 
(VD3, 100nM) treatment and Runx2 expression 
vector co-transfection, were used as positive 
controls. VD3 activation depends on endogenous 
vitamin D receptor. As expected, VD3 induced 
the human osteocalcin promoter. In the absence 
of DMSO, maximal expression was seen with 
VD3 and Runx2 treatment (6.8-fold). In the 
presence of DMSO, a significant boost to 
induction was seen, up to 18.5-fold (p<10-9, Fig. 
2G). An increase in osteocalcin induction in 
MC3T3-E1 cells after 24 hours exposure to 
DMSO treatment (in OM) is consistent with 
additional transcription factors being available to 
enhance promoter activity. 
Quantitative assays for the 
phosphorylation status of protein kinases across 
the first 30 hours in OM plus DMSO compared 
with OM found no convincing involvement of 
DMSO in ERK1/2, p38MAPK and JNK 
signalling pathways. Significant increases in 
phosphorylated signalling factors were seen after 
30 hours, with 2.8-fold (p=4.8x10-7), for 
phospho JNK, 1.8-fold (p=7.8x10-5) for phospho 
ERK and only 1.4-fold (p=8.6x10-6) for phospho 
p38MAPK. Significant effects of DMSO on 
phosphorylated kinases were observed for ERK 
(p=0.009) and JNK (p=0.014), however these 
were only minor decreases in DMSO treated 
cells (10% and 7% decreases for ERK and JNK, 
respectively). There were no significant effects 
on total kinase content between OM and OM 
plus DMSO treatments at any time point for 
ERK1/2, p38MAPK or JNK (data not shown), 
although total kinase increased over time.  
Finally we considered if the pool of 
phosphorylated kinase over total kinase changed 
according to DMSO: once again there were no 
significant DMSO related changes within 30 
hours. Furthermore, experiments with inhibitors 
of these pathways at appropriate concentrations 
did not suggest a role for the following inhibitors 
and pathways in the DMSO effect: U0126 for 
the ERK1/2 pathway, SB203580 for the 
p38MAPK pathway and Ly-294002 for the 
PI3/AKT pathway. The p38MAPK inhibitor 
SB203580 is reported to inhibit osteoblast gene 
activation through phosphorylation of osterix 
(19). Consistent with this observation, 
SB203580 decreased ALP activity in a dose 
dependent manner in MC3T3-E1 cells grown in 
OM; however the DMSO enhancement was still 
proportional to the reduced ALP activity (Fig. 
2H). Taken together these data suggest that the 
initial effects of DMSO action in osteoblasts 
occurs in a critical 72 hour window and may 
involve enhanced induction of osteocalcin at the 
transcriptional level (based on promoter 
transfection) but seems unlikely to involve 
p38MAPK, ERK1/2, JNK, or Pi3K/Akt at least 
within the first 30 hours. Those effects observed 
were either in the reverse sense to a DMSO 
mediated enhancement effect or were minor 
enough in magnitude as to be discounted. 
DMSO treatment is associated with 
increased expression of osteoblast markers - 
DMSO was clearly able to enhance osteoblast 
differentiation as revealed by elevated ALP 
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activity and mineralization. We next set out to 
investigate the effects of DMSO on osteoblast 
gene expression. Accordingly, the expression of 
marker genes was assessed at multiple time 
points throughout osteoblast differentiation. 
Cells were grown in osteogenic conditions over 
a period of 19 days and were harvested for qPCR 
analysis of endogenous gene expression at 
numerous time points (Fig. 3). Gene expression 
was expressed as fold change in transcript levels, 
measured by qPCR, referenced to zero time.  
Transcript levels for endogenous mouse 
osteocalcin (mouse gene Bglap2) were 
approximately doubled by DMSO treatment, 
reaching a peak at day 7 (Fig. 3A). Similar 
changes were seen in integrin binding 
sialoprotein (Ibsp, Fig. 3B), matrix 
metalloproteinase 13 (Fig. 3C) and the osteoclast 
differentiation factor, receptor activator of 
NFKappa-b ligand (Rankl, Fig. 3D). Not all 
extracellular matrix protein genes were induced 
by DMSO: dermatopontin (Dpt) was potently 
repressed by DMSO (Fig. 3E). The expression of 
osteoblast transcription factor, osterix (Osx, Fig. 
3F), was significantly increased by DMSO 
treatment at three days, and showed increased 
transcript levels at later time points, suggesting 
that DMSO treatment results in an early and 
sustained increase in a key osteoblast specific 
transcription factor. The upregulation of osterix 
within 3 days may be sufficient to explain 
DMSO enhanced osteocalcin promoter activity 
in transfection (Fig. 2G) and the continued 
upregulation of osterix over 21 days may be 
sufficient to explain enhanced mineralization: 
further work is required to directly test such 
hypotheses. Runx2 transcript levels were not 
significantly different at early time points 
between DMSO treated and control cells and, 
although Runx2 transcript levels were higher in 
DMSO treated cells as Runx2 increased over 
time, this was only nominally significant 
(p=0.03) at one time point (Fig. 2G). 
  Identification of genes super-induced by 
DMSO via genechip expression analysis and 
verification by qPCR - Differentiating MC3T3-
E1 cells treated with DMSO clearly produced 
significantly greater amounts of mineralized 
matrix. One of the potential uses of DMSO-
enhanced mineralization was to search for genes 
over-expressed as a consequence of DMSO 
treatment, effectively serving as a screening tool 
to identify novel genes involved in osteoblast 
differentiation and function. To search for genes 
super-induced by DMSO, we used affymetrix 
genechip microarrays to quantify gene 
expression in MC3T3-E1 cells grown under 
three different experimental conditions: standard 
medium which did not induce differentiation 
(non-mineralizing control); osteogenic medium 
which induced ECM mineralization (OM); and 
osteogenic medium supplemented with DMSO 
which produced highly mineralized matrix (OM 
plus DMSO). Cells were harvested for RNA 
extraction after twelve days of culture: this time 
point was chosen because four out of five 
osteoblast-expressed genes (Osx, Ibsp, Mmp13 
and osteocalcin) were significantly elevated as a 
consequence of DMSO treatment as reported 
above.  
 To identify DMSO super-induced genes, 
we applied two search filters to the microarray 
gene expression data. Firstly, all the genes that 
were at least moderately expressed (signal 
intensity over 100) and induced by more than 3-
fold in OM relative to control were selected. 
These genes were further filtered by selecting 
only those which were a further increased more 
than 1.5-fold by DMSO. The filtering process 
resulted in the identification of 28 genes super-
induced by DMSO (Table 2). DMSO treatment 
resulted in the super-induction of genes known 
to participate in bone biology such as 
osteoprotegerin (Tnfrsf11b) and integrin binding 
sialoprotein (Ibsp). Since osterix was induced by 
DMSO (Fig. 3F) we reasoned that any other 
transcription factor that is upregulated by DMSO 
in mineralizing MC3T3-E1 cells is a candidate 
for an osteoblast transcription factor with a role 
in mineralization. Mef2c transcription factor was 
identified as a DMSO super-induced gene on 
array. 
 Transcript profiling of Mef2c during 
osteoblast differentiation - To confirm the 
validity of the microarray results, we performed 
qPCR analysis in MC3T3-E1 cell experiments, 
to verify the expressions of Ibsp and Mef2c (Fig. 
4A and 4B). Relative to the control cells cultured 
in MEM, Ibsp expression was significantly 
induced 16-fold and 82-fold in OM and OM plus 
DMSO cultures, respectively, confirming the 
microarray. Similarly, Mef2c gene expression 
was upregulated 10-fold and 60-fold in OM and 
OM plus DMSO samples, respectively, relative 
to control. Mef2c gene expression was assessed 
during a time course of MC3T3-E1 
differentiation (Fig. 4C), showing that Mef2c 
expression levels increased during the initial 
stages of differentiation, peaking at day seven 
before decreasing by day 13. Mef2c transcript 
6 
 
levels are induced up to 100-fold by culture in 
mineralizing medium. In cells treated with 
DMSO, the peak of Mef2c induction was earlier 
(5 rather than 7 days) and induction was more 
sustained at later time points. In these respects, 
the DMSO effect on Mef2c induction in MC3T3-
E1 cells was similar to that observed for osterix 
(see Fig. 3F).  
The induction of Mef2c was confirmed 
in mouse primary osteoblasts. Mouse calvarial 
osteoblasts were isolated and cultured in OM in 
the presence of DMSO. Similar to the results in 
MC3T3-E1 cells, Mef2c was induced in calvarial 
osteoblasts during culture in OM compared to 
control medium (Fig. 4D) and Mef2c expression 
was further enhanced by DMSO. Furthermore, 
DMSO enhanced mineralization by calvarial 
osteoblasts (Fig. 4E). These data confirm the cell 
line MC3T3-E1 as a reasonable model for Mef2c 
effects in osteoblasts. Furthermore, in order to 
verify that Mef2c has effects on osteoblast 
biology that occur in a manner independent of 
DMSO, the following experiments represented 
in figures 6 through 9 were done completely in 
the absence of DMSO in culture. 
Mef2c expression in osteoblasts in vivo 
- Immunohistochemistry was used to detect 
Mef2c protein in mouse osteoblasts (Fig. 5). 
Positive staining was seen in 15 day fetal mouse 
skull (Fig. 5A) in the maxilla and mandible (Fig. 
5B and C), where staining was found in 
association with developing bone and was 
stronger than in adjacent Meckel’s cartilage (Fig. 
5C). Cells immediately adjacent to the bone 
surface were positive for Mef2c (Fig. 5D). In 
adult mouse bone, positive staining was found in 
the growth plate associated with hypertrophic 
chondrocytes and cells lining bone in the 
cancellous region (Fig. 5E). In adult femoral 
cortical bone, similar positive cells lining the 
bone surface were observed (Fig. 5F). Staining 
was also observed in osteocyte-like cells in 
lacunae in adult cortical bone (Fig. 5G). 
Mef2c gene silencing results in defective 
osteoblast differentiation – Mef2c expression in 
MC3T3-E1 cells followed a similar pattern to 
that of osterix and was enhanced by DMSO, 
suggesting Mef2c as a candidate bone 
transcription factor. This was tested using a 
Mef2c expression vector transfected into 
MC3T3-E1 cells. Mef2c mRNA levels were 
increased and significant increases in 
endogenous osteocalcin and Isbp transcript 
levels were observed (Fig. 6A, B and C). In a 
separate transfection, cultured over 16 days, 
significantly increased mineralization was 
observed in Mef2c transfected cells (Fig. 6D). 
Since Mef2c transfection elevated the expression 
of osteoblast genes, we would expect Mef2c 
knock down to have the reverse effect if the 
expression of osteocalcin and Ibsp is dependent 
on Mef2c. Mef2c expression was selectively 
knocked down using shRNAi-mediated gene 
silencing. One published (17) and two novel 
shRNAi sequences targeting three separate 
regions of the Mef2c sequence were designed 
and cloned into pSIREN-RetroQ (Sh1, Sh2 and 
Sh3). A shRNAi sequence targeting firefly 
luciferase mRNA was used as a control (Shlux). 
Pooled stably transfected MC3T3-E1 cell lines 
were generated via retroviral transduction and 
used in differentiation experiments.  
Targeting of Mef2c transcripts with 
shRNA resulted in highly significant and 
consistent decreases in Mef2c expression levels 
throughout MC3T3-E1 osteoblast differentiation 
(Fig. 7A). The rank order of effectiveness of 
Mef2c shRNAs from least to most effective was 
Sh1, Sh2 then Sh3. Although these knock 
down cell lines had a slightly decreased rate of 
proliferation that was significant statistically 
(Fig. 7B), the magnitude of this effect was not 
large enough to explain observed biological 
effects. The impact of selectively reducing 
Mef2c expression levels on osteoblast 
differentiation was investigated. Targeting of 
Mef2c transcripts resulted in highly significant 
reduction in ALP activity (Fig. 7C), with one 
cell line, Sh3, showing almost total suppression.  
The accrual of mineral through the time course 
was dramatically suppressed (Fig. 7D) and a 
delay in the onset of visible bone nodule 
formation was observed (Fig. 7E). Highly 
significant reductions in mineral accrual 
occurred in all shRNA cell lines (Fig. 7D and E) 
culminating in up to 10-fold reduction by day 21.  
The magnitude of decreased ALP 
activity was correlated to the potency of Mef2c 
silencing such that Sh3, which mediated the 
greatest reduction in Mef2c expression, produced 
the largest reduction in ALP activity, suggesting 
that ALP activity was dependent on Mef2c levels 
in the cells. However, suppression of 
mineralization appeared similar in all three 
knock-down cells lines.  
Knock down of Mef2c transcript is 
associated with significant decreases in 
osteoblast gene expression - Knockdown of 
Mef2c clearly resulted in reduced mineralization 
and ALP activity. In order to determine if this 
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was due to a block in osteoblast differentiation 
(where lack of induction of osteoblast specific 
genes might be expected) or a block in 
mineralization due to the singular loss of ALP 
activity, gene expression of osteoblast marker 
genes was examined by qPCR. If Mef2c is 
necessary for the differentiation of osteoblasts, 
and acts as an osteoblast transcription factor, a 
flow-on knockdown of osteoblast related gene 
expression should be observed.  
Osteoblast related genes Ibsp and 
osteocalcin, that were upregulated by DMSO, 
were strongly suppressed in anti-Mef2c shRNAi 
cell lines (Fig. 8A and B, respectively), and in a 
manner related to the extent of Mef2c 
knockdown. Cell line Sh3 had the most potent 
knockdown, with almost complete suppression 
of Ibsp and osteocalcin gene expression and flow 
on knockdown of Mmp13 (Fig. 8C). Recall that 
in DMSO treated cells (see Fig 3), 
dermatopontin (Dpt) transcript levels were 
suppressed by DMSO treatment (in which Mef2c 
expression was increased). In the Sh3 cell line, 
in which Mef2c is almost completely suppressed, 
a potent time-dependent induction of 
dermatopontin message was observed during 
culture in OM (Fig. 8D), suggesting Mef2c is a 
negative regulator of dermatopontin. These data 
suggest that Mef2c knockdown, at least in Sh3 
cells line, results in the inverse phenotype to that 
of DMSO treatment: inhibited mineralization 
coupled with a lack of ALP activity, failure to 
induce osteoblast marker genes and a strong 
induction of Dpt. Flow on knock down of osterix 
was significant in the comparison of control 
Shlux to all knock down cell lines (Sh1, p=0.02; 
Sh2, p=0.02, data not shown) and was strongest 
in Sh3 cell line (p<10-6, Fig 8E). In Sh3 relative 
to Shlux, the knock down of osterix was 
significant at all time points including time zero 
(p=1.0x10-4). Flow on knockdown of Runx2 
(p=0.004, Fig. 8F) was observed in Sh3: such 
flow on knock down suggests that Mef2c is 
upstream of these key transcription factors in the 
cascade of gene expression involved in 
osteoblast differentiation. Runx2 has an 
osteoblast specific isoform (Runx2-II, 20) driven 
off the upstream promoter: this message was 
also suppressed 12-fold in Sh3 relative to Shlux 
(p=0.002, data not shown) in a manner similar to 
the data for general Runx2 isoforms (Fig. 8F).  
Gene expression in MC3T3-E1 cells 
with Mef2c knockdown - In order to verify the 
finding that osteoblast differentiation was 
blocked by Mef2c knockdown, we investigated 
the consequences of Mef2c gene silencing on the 
expression of genes in cells undergoing 
osteoblast differentiation. Shlux and Sh3 cells 
were induced to differentiate into osteoblasts via 
the addition of OM and were harvested 3, 10 and 
19 days for microarray gene expression analysis. 
Low signal data (<100) were rejected 
and genes considered of interest if they were 
either highly induced, had high signal value that 
varied between day 3 and 10 or was different 
comparing control Shlux to Mef2c knock down 
cell line Sh3. The difference expected in Mef2c 
transcript level due to knockdown was observed 
in the array data (Fig. 9A). The top ranked genes 
for the absolute difference between day 3 and 
day 10 in control Shlux cells during growth in 
OM were mouse osteocalcin (Bglap2) and 
osteocalcin related genes (Bglap1 and Bglap-
rs1). The next in rank were Ibsp, and Mmp13. 
The osteocalcin related genes (Bglap1, Bglap2 
and Bglap-rs1), Ibsp and Mmp13 were also the 
top rank of strongly suppressed genes in array 
comparison between Sh3 (Mef2c knock down 
cell line, Fig. 9B, C and D) compared to Shlux, 
confirming that the array detected the same gene 
changes as seen previously using qPCR. These 
observations validated the array as a discovery 
tool to identify candidates for further work 
related to Mef2c action in osteoblasts. Regulated 
genes that are highly expressed on array and that 
were represented by multiple probes sets in the 
array platform are presented in Fig. 9. The 
parathyroid hormone receptor (Pthr1) was 
identified as increased by DMSO (Table 2): 
Pthr1 was significantly increased during 
osteoblast differentiation in Shlux and was 
suppressed in Sh3 cell line (Fig. 9E) suggesting 
positive regulation of Pthr1 by Mef2c. Collagen 
type 2 alpha 1 (Col2a1) was similarly affected 
by Mef2c knockdown (Fig. 9F). As expected, 
both Runx2 and osterix transcripts were 
significantly reduced on the array (Fig. 9G and 
H), consistent with the analysis using qPCR (see 
Fig 8). Numerous other genes were affected by 
Mef2c knockdown, consistent with a global 
effect of Mef2c on gene expression in MC3T3-
E1 cells. The data suggest that Mef2c 
transcription factor is required for appropriate 
expression of the suite of osteoblast-specific 
genes that characterizes the cell phenotype and 
ultimately results in mineralizing activity. Table 
3 and 4 contain the genes displaying the largest 
fold changes in expression, regardless of 
magnitude of expression, between the two cell 
lines at each of the time points. 
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Finally, the osteocyte marker gene 
sclerostin (Sost) was also evaluated as the Sost 
promoter is a proposed target gene of Mef2c in 
osteocytes (21). In our hands, Sost expression 
was not detected in differentiating MC3T3-E1 
cells, either with DMSO or not, or with Mef2c 
knockdown, in any experiment using qPCR, 
indicated by non-detected cycle threshold values 
(data not shown). No array probe set showed 
signal over background in any array experiment. 
The absence of sclerostin expression suggests 
that under any of the conditions reported in this 
study, MC3T3-E1 cells do not acquire an 
osteocyte phenotype.  
 
DISCUSSION 
 
 In this study, we showed that DMSO 
treatment was able to stimulate mineralization of 
human osteoblasts in primary culture. Increasing 
the mineralization potential of such cells may be 
useful in tissue engineering for replacement of 
mineralized tissues. Similarly, primary adipose 
derived mesenchymal cells were stimulated by 
DMSO to produce more mineral, as were 
primary mouse calvarial cells, suggesting that 
DMSO enhancement is a general phenomenon 
applicable to osteoblast culture.  We then used 
the pre-osteoblast cell line MC3T3-E1 to 
investigate DMSO enhance osteoblast 
differentiation and as a tool to identify novel 
regulators of differentiation. We first established 
the optimal DMSO concentration required to 
enhance differentiation through dose response 
curves. We next investigated the impacts of 
DMSO enhanced differentiation through time 
course experiments. The results showed that 
DMSO facilitated increases in ALP activity and 
mineralization and the increases were sustained 
throughout differentiation. It seems likely that 
DMSO treated cells achieved a heightened state 
of differentiation reflected by an enhanced 
capacity to mineralize the surrounding 
extracellular matrix. Cheung et al. (12) 
examined Runx2 and osterix induction by 
DMSO in normal MEM medium at five days 
only; Runx2 (1.89-fold) and osterix (1.39-fold) 
induction by DMSO was significant. In contrast, 
we examined the effect of DMSO on target gene 
expression using a number of target genes at 
numerous time points in osteogenic medium 
(OM); in particular, we observed strong 
induction of osterix by DMSO over the entire 
time period of mineralization, including day 
three and five. In addition, we defined Mef2c as 
a target of DMSO induction. A critical period of 
the first three days was seen where DMSO 
exposure was sufficient to generate the maximal 
enhancement, a fact that may prove useful in 
tissue engineering. Investigations of that three 
day period showed that endogenous osterix was 
significantly elevated at three days treatment 
with DMSO and that enhancement of a 
transfected osteocalcin promoter can occur 
within that period. Although the mechanism of 
DMSO effect remains to be elucidated, it seems 
likely that the mechanism will involve 
transcription factors. Further work is needed to 
fully define the early effects of DMSO on gene 
expression in osteoblasts. DMSO has other 
effects in bone biology. Zyuz’kov et al. (31) 
show that DMSO treatment (for 5 days at 2g/kg) 
via gastric tube in mice, results in a decrease of 
colony forming unit-fibroblast (CFU-F) derived 
from the stromal fraction in bone marrow 
cultures at eight days. We also tested DMSO on 
osteoclast differentiation and found profound 
stimulation, particularly in the size of osteoclasts 
(unpublished data). To our knowledge, no 
experiments have been reported specifically 
addressing bone anabolic effects of DMSO in 
vivo. A more complete analysis of the effects of 
DMSO on bone in vivo is warranted, as 
osteoblasts, osteoclasts and stromal cells may be 
affected by DMSO.  
Gene expression studies revealed that 
osterix, Ibsp, osteocalcin and Mmp13 were 
increased as a consequence of DMSO treatment 
and provided evidence that key regulators of 
osteoblast function were altered by DMSO, 
consistent with an enhanced state of osteoblast 
differentiation. Microarray analysis revealed 
Mef2c as a novel factor involved in osteoblast 
differentiation. Mef2c is a MADS-box 
transcription factor that has pleiotropic effects 
with examples including heart development (22), 
cardiac hypertrophy (23), myeloid cell fate (24), 
and skeletal muscle differentiation (25), among 
many other effects. In addition, the Mef2c locus 
has recently been linked genetically to human 
bone mineral density (26). More germane to 
bone mineralization are observations of Arnold 
et al. (27), using various conditional Mef2c 
knock out mice, that Mef2c is expressed in 
hypertrophic chondrocytes and is involved in 
endochondral ossification. Our ex vivo models 
suggest that Mef2c is not restricted to the 
chondrocyte, but functions as a key osteoblast 
transcription factor upstream of both Runx2 and 
osterix in osteoblasts. We detected reasonable 
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expression of Col2a1, at least in MC3T3-E1 
cells by gene array. Sakai et al. (28) detected 
expression of the Col2a1 promoter in mouse 
osteoblasts in vivo, using a  galactosidase 
indicator line (Rosa26) crossed with a Col2A1 
promoter driving CRE, suggesting some 
commonality between chondrocytes and 
osteoblasts. Arnold et al. (27) reported that the 
Col2A1 promoter was regulated by Mef2c. 
Consistent with that fact, we observed flow-on 
knock down of Col2A1 in Mef2c knock down 
cell lines. Combining these lines of evidence, it 
seems likely that Mef2c acts in osteoblasts as 
well as chondrocytes.  
Transcript profiling revealed Mef2c was 
dynamically regulated during MC3T3-E1 
osteoblast differentiation and increased during 
primary calvarial osteoblast differentiation. In 
MC3T3-E1 cells, two distinct peaks in Mef2c 
gene expression were observed and coincided 
with the developmentally relevant time points 
(see 29) of day seven, where the cells slow their 
proliferation and begin to differentiate and days 
16-19, where cells enter the terminal stages of 
differentiation and actively mineralize. The 
addition of DMSO to the culture medium 
resulted in an accelerated pattern of Mef2c gene 
expression whereby the first peak in expression 
was earlier and the second peak more substantial. 
Notably, the expression of Mef2c during the 
terminal stages of differentiation (days 13-19) 
was significantly elevated in DMSO-treated cells 
introducing the possibility that Mef2c could 
function as a regulator of mineralization. 
Immunohistochemical analysis showed 
Mef2c in embryonic and adult mouse in cells 
associated with bone. Although such cells were 
not formally identified as osteoblasts using other 
markers, it seems reasonable to conclude that 
osteoblasts express Mef2c. Furthermore, 
transfection of Mef2c expression vector into 
MC3T3-E1 cells resulted in increased 
osteocalcin transcript and increased alkaline 
phosphatase activity suggesting that Mef2c can 
function in osteoblasts. Short hairpin mediated 
gene knock down in MC3T3-E1 cells, confirmed 
the functional role for Mef2c in osteoblast 
differentiation. The consistent knock down of 
Mef2c mRNA levels was linked to potent 
reductions in ALP activity throughout 
differentiation. ALP participates in inorganic 
phosphate homeostasis and is associated with 
matrix vesicle mineralization (30). Therefore, it 
was not surprising to observe that mineralization 
was also disrupted in Mef2c shRNAi expressing 
cells. Furthermore, the key osteoblast specific 
gene, osteocalcin, was suppressed in Mef2c 
knock down cell lines and, of all genes assayed 
by gene array, the osteocalcin related gene 
cluster (Bglap1, Bglap2 and Bglap-rs1) were the 
top rank of genes altered by Mef2c knock down. 
The data suggest an essential role for Mef2c in 
regulating osteoblast differentiation.  
A potential mechanism via which Mef2c 
could regulate osteoblast differentiation is 
controlling the expression of Runx2 and osterix, 
which were both significantly knocked down at 
the mRNA level as a flow on from Mef2c knock 
down. This possibility is strengthened by the fact 
that osteocalcin is known to be regulated directly 
by Runx2 and osterix. Further work is needed to 
determine if Mef2c has a direct or indirect effect 
on osteocalcin promoter. The comparative 
analysis of gene expression between Shlux and 
Sh3 cells using microarrays revealed many 
differentially regulated genes, consistent with 
Mef2c being necessary for the maintenance of 
osteoblast specific gene expression. Notably, the 
lowered expression of several known osteoblast 
regulators, (such as Akp2, Ibsp, Mmp13, and 
Pthr1) indicated Sh3 cells had a general inability 
to differentiate correctly.  
We could not detect Sost expression 
using q-PCR or gene array, arguing strongly that 
the DMSO treated cells do not adopt an 
osteocyte-like phenotype. Mef2c is proposed to 
mediate the regulation of the Sost enhancer by 
PTH (21). In our study, Mef2c knock down 
resulted in flow on knock down of Pthr1 (the 
PTH receptor), suggesting an alternative 
connection between Mef2c and PTH that may 
operate in osteoblasts. This can be clarified in 
future studies.   
 In conclusion, we have demonstrated 
that DMSO has profound effects on the 
differentiation of human osteoblasts, mouse 
adipocyte derived primary cells, mouse calvarial 
osteoblasts and the model cell line MC3T3-E1. 
Treatment with DMSO resulted in highly 
significant increases in ALP activity and mineral 
deposition in each of these osteoblastic cell 
models. We used DMSO-enhanced MC3T3-E1 
differentiation as a tool to screen for factors 
involved in the developmental process. Our 
search identified Mef2c as a candidate osteoblast 
transcription factor, whose expression was 
verified in mouse primary calvarial cells. 
shRNAi-mediated gene silencing in MC3T3-E1 
cells demonstrated that Mef2c was required for 
proper osteoblast differentiation and function. 
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Our data suggests Mef2c has an important role 
in osteoblast biology and is required for proper 
osteoblast differentiation and matrix 
mineralization. We suggest that Mef2c is a key 
osteoblast transcription factor, upstream of 
Runx2 and osterix, and worthy of further study 
in osteoblast biology. Combined with its role in 
chondrocyte hypertrophy, osteoblast biology 
(this study) and its presence in osteocytes, 
Mef2c is positive regulator of skeletal formation, 
mineralization and homeostasis at a number of 
levels.  
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FIGURE LEGENDS 
 
Fig. 1.  DMSO enhances alkaline phosphatase (ALP) activity and ECM mineralization in osteoblasts. 
Cultured human osteoblasts were grown for the times shown in MEM (black columns), osteogenic 
medium (gray columns, OM) or OM supplemented with DMSO (striped and checked columns) and 
assessed for ALP activity (A) and ECM mineralization (B). Mouse adipocyte derived mesenchymal 
cells were cultured in a similar manner, with similar results including (C) increased ALP activity and 
(D) increased mineralization associated with DMSO treatment at the concentrations indicated. Data 
represent mean ± SEM of at least three independent samples. 
 
Fig. 2.  DMSO enhances alkaline phosphatase (ALP) activity and ECM mineralization of a model 
osteoblast cell line (MC3T3-E1). Differentiating MC3T3-E1 cells were treated with various 
concentrations of DMSO and assessed for ALP activity (A) and ECM mineralization (B). Insert photo 
in B shows mineral nodule formation, visualized using Alizarin Red S, with increasing DMSO at day 
12. Levels of ALP activity (C) and ECM mineralization (D) during osteoblast differentiation time 
courses in control cultures (OM medium, black triangles) and OM plus DMSO treated cells (0.55 % 
DMSO, black squares). The time of exposure of cells to DMSO altered the mineralization outcome 
(E), with the first 3 days of culture being critical for the maximal effect of DMSO. (F) Cell 
proliferation was only mildly suppressed by DMSO: MC3T3-E1 cells were seeded at 1 x 104 cells per 
well in 24-well culture plates and treated with various concentrations of DMSO. The cells were grown 
over a period of four days and cellular proliferation was assessed on each day via the MTT method. 
(G) DMSO treatment in OM results in increased induction of transfected human osteocalcin promoter 
within the first 72 hour of exposure: human osteocalcin promoter driving luciferase (pOSLUC) was 
transfected into MC3T3-E1 cells and induction measured after 72 hours in OM alone (black columns) 
or OM with exposure to DMSO for the last 24 hours (gray columns). Treatments included 
cotransfection of 100ng Runx2 expression vector and/or treatment with 100nM 1,25dihydroxyvitamin 
D3 (VD3) to induce the osteocalcin promoter. (H) DMSO enhancement of ALP activity in MC3T3-E1 
is resistant to the p38MAPK inhibitor SB203580. Enhancement by DMSO still occurred from the 
lower basal level that results from inhibition of p38MAPK pathway by SB203580. Cell culture was 
12 days. Error bars are ± SEM of at least three independent samples. P values omitted since effects 
are large.  
 
Fig. 3.  DMSO significantly increases the expression of osteoblast markers during differentiation. 
Osteogenic medium (OM, black circles, black line) was compared to OM plus 0.55% DMSO (gray 
circles, gray line). MC3T3-E1 cells were harvested at various time points during osteoblast 
differentiation for quantitative gene expression analysis of osteocalcin (OSC, graph A), integrin 
binding sialoprotein (IBSP, graph B), matrix metalloproteinase 13 (MMP13, graph C) and receptor 
activator of NFkappa-b ligand (RANKL, graphs D). Remarkably, dermatopontin (DPT, graph E) was 
completely repressed by DMSO in osteogenic medium, in comparison to OM control. The osteoblast 
transcription factor osterix (graph F), was significantly induced by DMSO most time points assessed, 
including 3 days. Runx2 (graph G) was not significantly different early in DMSO treatment and 
although of greater magnitude in DMSO treated cells, was significantly different with respect to 
DMSO at day 10 only (asterisk, p=0.03). Data represent mean ± SEM of three independent samples. 
In graphs A-F, asterisks denote significantly different to OM (for that time point) at p < 0.01. Overall 
p values (not shown for each) of the treatment effect for DMSO were determined using the general 
linear model based analysis of variance and all were <10-6, except for Runx2 (graph G) which was not 
significant. 
 
Fig. 4.  DMSO treatment results in the super-induction of Ibsp and Mef2c gene expression in 
osteogenic medium (graphs A and B, respectively). Cells were grown in MEM (MEM, black 
columns), osteogenic medium (OM, gray columns) and osteogenic medium supplemented with 0.55% 
DMSO (DMSO, striped columns) for 12 days. Transcript profiling of Mef2c during osteoblast 
differentiation according to time (graph C) confirms sustained induction during osteoblast 
differentiation in OM (black circles) and super induction by DMSO addition in OM (gray circles).  
Mef2c is induced during mouse calvarial cell cultures and shows super-induction with DMSO (graph 
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D): Mef2c transcript levels were compared in calvarial osteoblasts grown in MEM (MEM, back 
diamonds, striped line), OM (black circles, black line) and OM plus 0.55% DMSO (DMSO, gray 
circles, gray line). Photograph (E), shows mineralization of mouse calvarial osteoblasts in MEM 
(MEM), OM, and OM plus 0.55% DMSO (DMSO) indicating enhancement of mineralization effect 
in calvarial osteoblasts by exposure to DMSO.  * denotes significantly increased compared to OM (p 
< 0.01). Other P values omitted since effects are large (graphs A and B).  
 
Fig. 5.  Mef2c is present in osteoblasts. A. Immunohistochemistry of day 15 embryonic mouse head 
(parasagittal section, A), showing immuno-reactivity (brown stain) in the mandible and the maxilla 
(boxes). B and C. Boxes in image A are shown in greater detail; staining is positive in the maxilla (B) 
and the mandible (C). Arrows indicate examples of positive stain associated with developing bone: 
Meckel’s cartilage is indicated (m in C). Bars are 200M. D. Increased magnification of arrow 
location in C shows numerous positive staining cells around the developing bone (bar is 20M). E. 
Analysis of adult mouse bone shows staining in the hypertrophic chondrocytes of the growth plate 
(white arrow) and in sites immediately adjacent to bone (black arrow). Bar is 100M. F. Adult mouse 
cortical bone shows bone lining cells stain positive for Mef2c. G. Osteocytes in lacunae of cortical 
bone stain positive for Mef2c. Bars in F and G are 20M. 
 
Fig. 6. Knock in expression of Mef2c by transfection in MC3T3-E1 cells results in increased 
expression of Mef2c (graph A), osteocalcin (OSC, graph B) and integrin binding sialoprotein (IBSP, 
graph C). MC3T3-E1 cells were transfected and grown subsequently in OM for the specified time 
before harvest and assessment of mRNA levels by q-PCR. All genes are significantly increased by 
Mef2c transfection at 7 days (p<0.001). D. In a separate transfection experiment, cultured to 16 days, 
a significant increase in extracellular matrix mineralization was observed in Mef2c transfected cells 
compared with empty vector transfected control (p=4x10-4). 
 
Fig. 7.  shRNA mediated silencing of Mef2c gene expression: graph A shows the effectiveness of 
knock down of Mef2c transcript levels in control (Shlux, black columns, a non target shRNA) 
compared with three cell lines, Sh1, Sh2 and Sh3 (gray, striped and checked columns, respectively) 
with varying levels of Mef2c knock down. Significant knock down was obtained at all time points 
with Sh3 cell line exhibiting the greatest extent of knock down (p values not included since effects are 
large). Knock down cell lines have a minor decrease in cell proliferation (B) that does not explain the 
extent of knock down of alkaline phosphatase (ALP) activity (graph C) or knock down of 
mineralization which is nearly total in all cell lines (graph D). Cell lines Sh1 and Sh2 that had very 
minor decrease in proliferation, still had major suppression of mineralization. In addition, the 
appearance of visible bone nodules (Alizarin Red S stain, image E) was delayed in Mef2c knock down 
cell lines.  
 
Fig. 8. Mef2c knock down results in flow on knock down of osteoblast specific genes. qPCR was used 
to determine transcript levels for candidate osteoblast related genes. Those genes that were induced by 
DMSO were repressed by Mef2c knock down. Integrin binding sialoprotein (IBSP, graph A), 
osteocalcin (OCS, graph 2) were knocked down in a manner correlated with extend of Mef2c 
knockdown in Sh1, Sh2 and Sh3, compared with control Shlux. The most extreme knock down line 
Sh3, was then examined. Matrix metalloproteinase 13 (MMP13, graph C) showed flow-on knock 
down (graph C) and dermatopontin (DPT, graph D) showed the reverse effect: flow on gene induction 
resulting from Mef2c knock down, suggesting that Mef2c acts as a repressor of this gene. Comparing 
Mef2c knock down cell line Sh3 against control (Shlux) demonstrated similar flow-on knock down of 
osteoblast transcription factors osterix (p=0.001, OSX, graph E) and Runx2 (p=0.004, RUNX2, graph 
F). Transcript levels are relative to zero time in OM, except for osterix which was different at zero 
time: that is, transcript levels of osterix were already detectably different prior to culture in OM. P 
values in experiments A to D are all <10-6 for the overall effect in the generalized linear model.   
 
Fig. 9. Differential expression of osteoblast related genes resulting from Mef2c knock down. Shlux 
and Sh3 cells were induced to differentiate into osteoblasts via the addition of OM. Cells were 
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harvested 3, 10 and 19 days in OM for whole-genome microarray gene expression analysis. Genes 
with large changes in absolute signal and with repeated probe sets on array are shown. Significant 
differences were observed for Mef2c (A, MEF2C), osteocalcin related sequences (Bglap-rs1, B), 
osteocalcin (OSC, C), integrin binding sialoprotein (IBSP, D), parathyroid hormone receptor (PTHR1, 
E), alpha 1 chain of type 2 collagen (COL2A1, F), transcription factors Runx2 (RUNX2, G), and 
osterix (OSX, H). Transcript levels represent the microarray intensity values, error bars are SEM, 
significance was based on two factor ANOVA using all time points and all data values (p values are 
all <0.006 for effect of Mef2c knock down, except Runx2 which has p=0.03). 
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TABLES 
Table 1. Real-time qPCR primers used in the study and oligonucleotide sequences of Mef2c targeting 
shRNAs 
 
 
Name  Forward (5’-3’) Reverse (5’-3’) 
Genes Accession No.   
Ibsp NM_008318 gcgtcactgaagcaggtg cggtaagtgtcgccacgag 
Mef2c NM_025282 gctgagatacgcttagcacttgagt cgggtctgtccaaacctctataca 
Osc NM_001032298 gcagacaccatgaggaccc ggtctgatagctcgtcacaagc 
Osx NM_130458 tggaatgtaccccagtcctctcgac ccaggccttgcacatattaagcatt 
Runx2 NM_009820 cagtcacctcaggcatgtc gcgtgctgccattcgag 
Runx2-II NM_009820 ccaggaagactgcaagaagg tattcctgcatggactgtggtt 
Actb NM_007393 ctctggctcctagcaccatgaaga gtaaaacgcagctcagtaacagtccg 
B2m NM_009735 ctgctacgtaacacagttccaccc catgatgcttgatcacatgtctcg 
Hmbs NM_013551 gagtctagatggctcagatagcatgc cctacagaccagttagcgcacatc 
Hprt1 NM_013556 gaggagtcctgttgatgttgccag ggctggcctataggctcatagtgc 
Dpt NM_001937 agatatacaccagcagacccaacag catgggaaagggagaattatccttc 
Sost NM_024449 caaccagtcggagctcaaggactt agtagagaccgcaggtccttctgc 
shRNAs Nucleotide 
target region* 
  
Sh1 531-549 gatccgaatagtatgtctcctggtttcaagaga
accaggagacatactattctttttg 
aattcaaaaagaatagtatgtctcctggttctctt
gaaaccaggagacatactattcg 
Sh2 682-700 gatccggtaacctgaacaagaatattcaagag
atattcttgttcaggttacctttttg 
aattcaaaaaggtaacctgaacaagaatatct
cttgaatattcttgttcaggttaccg 
Sh3 236-254 gatccggacaaactcagacattgtttcaagag
aacaatgtctgagtttgtcctttttg 
aattcaaaaaggacaaactcagacattgttctc
ttgaaacaatgtctgagtttgtccg 
*From ATG start codon of Mef2c mRNA (NM_025282). Ibsp, integrin binding sialoprotein; Mef2c, 
myocyte enhancer factor 2C; Osc, osteocalcin or bone gamma-carboxyglutamate protein 2; Osx, 
osterix or trans-acting transcription factor SP7; Runx2, runt related transcription factor 2; Actb, actin, 
beta; B2m, beta-2 microglobulin; Hmbs, hydroxymethylbilane synthase; Hprt1, hypoxanthine guanine 
phosphoribosyl transferase; Dpt, dermatopontin; Sost, sclerostin. 
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Table 2. Genes super-induced by DMSO in differentiating osteoblasts 
Accession 
Number 
Fold change 
OM/CT 
Fold change 
DMSO/CT 
Fold change 
DMSO/OM 
Gene name Gene 
D17444.1 3.2 15.0 4.7 Soluble D-factor/LIF receptor Lifr 
NM_028943 14.0 54.9 3.9 Sphingomyelin synthase 2 Sgms2 
NM_025282.1 5.5 21.1 3.8 Myocyte enhancer factor 2C Mef2c 
NM_013703.1 6.5 
 
24.6 
 
3.8 
 
Very low density lipoprotein 
receptor 
Vldlr 
AK003671.1 27.7 100 3.7 Carbonic anhydrase 3 Car3 
NM_080440 9.3 
 
 
32.3 
 
 
3.5 
 
 
Solute carrier family 8 
(sodium/calcium exchanger), 
member 3 
Slc8a3 
AB013898.1 3.1 
 
10.5 
 
3.5 
 
Osteoclastogenesis inhibitory 
factor 
Tnfrsf11b 
BC004048.1 9.4 32.2 3.4 Wnt inhibitory factor 1 Wif1 
BB042892 5.7 
 
19.0 
 
3.3 
 
Ubiquitin-conjugating enzyme 
8 
Ubce8 
BE370703 8.4 27.7 3.3 Neutrophil cytosolic factor 1 Ncf1 
NM_153060 5.8 
 
16.3 
 
2.8 
 
Spinster homolog 2 Spns2 
BM240191 3.6 
 
10.1 
 
2.8 
 
Rho-associated coiled-coil 
forming kinase 1 
Rock1 
BI964347 3.3 
 
 
8.6 
 
 
2.6 
 
 
A disintegrin and 
metalloproteinase domain 12 
(meltrin alpha) 
Adam12 
XM_907370 4.3 11.2 2.6 Collagen, type XXII, alpha 1 Col22a1 
NM_021491 3.6 
 
8.7 
 
2.4 
 
Sphingomyelin 
phosphodiesterase 3 
Smpd3 
NM_172454 10.0 23.6 2. Pannexin 3 Panx3 
NM_153170 4.1 
 
 
9.7 
 
 
2.3 
 
 
Solute carrier family 36 
(proton/amino acid symporter), 
member 2 
Slc36a2 
NM_001081064 3.7 8.0 2.2 PDZ domain containing 2 Pdzd2 
L20232.1 21.2 42.8 2.0 Bone sialoprotein Ibsp 
NM_009760 2.9 5.6 2.0 BCL2/adenovirus E1B 
interacting protein 3 
Bnip3 
NM_011356 29.0 56.5 2.0 Frizzled-related protein Frzb 
NM_053083 3.0 5.8 1.9 lysyl oxidase-like 4 Loxl4 
NM_016894 3.9 7.4 1.9 Receptor (calcitonin) activity 
modifying protein 1 
Ramp1 
NM_009331 5.0 9.5 1.9 Transcription factor 7, T-cell 
specific 
Tcf7 
NM_019738 3.8 7.2 1.9 Nuclear protein 1 Nupr1 
NM_011199 4.1 6.9 1.7 Parathyroid hormone receptor Pth1r 
NM_030888 3.4 5.6 1.6 C1q and tumor necrosis factor 
related protein 3 
C1qtnf3 
NM_053088 32.6 52.4 1.6 Interferon induced 
transmembrane protein 5 
Ifitm5 
Results are shown as fold change in gene expression. Cells were cultured for 12 days post-induction 
of osteogenic differentiation. CT, control cells cultured in non-mineralising medium; OM, cells 
cultured in osteogenic medium; DMSO, cells cultured in osteogenic medium supplemented with 
DMSO. 
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Day 3 Day 10 Day 19 
Symbol Accession Fold Symbol Accession Fold Symbol Accession Fold 
Ly6a NM_010738 -3.9 Ccl7 NM_013654 -7.5 Ccl7 NM_013654 -7.1 
Tnnc1 NM_009393 -3.2 Abi3bp NM_178790 -4.6 Abi3bp NM_178790 -5.9 
Ly6c1 NM_010741 -3.2 Ly6a NM_010738 -4.6 Ly6a NM_010738 -5.1 
Loc100047583 XM_001479138 -2.76 Scl0002547.1_9 scl0002547.1_9 -4.1 Nme7 NM_138314 -4.8 
Tgm2 NM_009373 -2.7 Ifi27 NM_029803 -4.0 Txnip NM_023719 -4.4 
Gdpd2 NM_023608 -2.5 Txnip NM_023719 -3.8 Ecrg4 NM_024283 -4.4 
Pappa NM_021362 -2.4 Ccl5 NM_013653 -3.7 Htra3 NM_030127 -4.2 
6330406i15rik NM_027519 -2.4 Dcn NM_007833 -3.5 Atp1b1 NM_009721 -3.8 
Wisp2 NM_016873 -2.3 Klra4 NM_010649 -3.5 Mfap4 NM_029568 -3.7 
Nme7 NM_138314 -2.3 Ly6c1 NM_010741 -3.5 Papss1 NM_011863 -3.6 
Loc382972 XM_356781 -2.3 1500015o10rik NM_024283 -3.2 Robo1 NM_019413 -3.4 
Idb4 AK041164 -2.2 Figf NM_010216 -3.0 Ly6c1 NM_010741 -3.3 
Ifit3 NM_010501 -2.2 Loc100038894 XM_001471776 -3.0 Chst2 NM_018763 -3.1 
6330406i15rik NM_027519 -2.2 Ccl2 NM_011333 -3.0 Htra1 NM_019564 -3.1 
Ppap2b NM_080555 -2.1 Tnn NM_177839 -2.9 Mrgprf NM_145379 -3.1 
B230343a10rik scl41403.1.1_37 -2.1 Lum NM_008524 -2.9 Casp1 NM_009807 -3.0 
Abca3 NM_013855 -2.1 Syt1 NM_009306 -2.9 Alox5ap NM_009663 -3.0 
Nme7 NM_138314 -2.1 Txnip NM_001009935 -2.9 Il33 NM_133775 -3.0 
Cdkl5 NM_001024624 -2.1 Cdkl5 NM_001024624 -2.9 Cxx1a NM_024170 -3.0 
Sdpr NM_138741 -2.1 Id4 NM_031166 -2.8 Pigt NM_133779 -2.9 
 
Table 3. Genes displaying lowered expression in control cells (Shlux) compared to Mef2c shRNA 
knock down (Sh3) cells at days 3, 10 and 19 during osteoblast differentiation. Negative sign indicates 
repression, fold indicates change in Sh3 relative to Shlux.  
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Day 3 Day 10 Day 19 
Symbol Accession Fold Symbol Accession Fold Symbol Accession Fold 
Panx3 NM_172454 10.6 Cdsn NM_001008424 11.4 Spata19 NM_029299 14.2 
Ibsp NM_008318 7.1 Trib3 NM_175093 10.3 Timp4 NM_080639 13.8 
Mest NM_008590 4.5 Megf10 NM_00100197 9.9 Col10a1 NM_009925 10.4 
Smpd3 NM_021491 4.4 Cox6a2 NM_009943 8.3 Panx3 NM_172454 7.7 
Pthr1 NM_011199 4.3 Pthr1 NM_011199 8.0 Cox6a2 NM_009943 7.7 
Ifitm5 NM_053088 4.2 Chac1 NM_026929 6.5 Trib3 NM_175093 7.4 
H19 NR_001592 3.6 Sema7a NM_011352 6.3 Megf10 NM_001001979 7.3 
Tnfrsf19 NM_013869 3.5 Aldh1l2 NM_153543 6.2 Mef2c NM_025282 6.7 
Ramp1 NM_016894 3.4 Mef2c NM_025282 6.1 Krt14 NM_016958 6.4 
Mef2c NM_025282 3.3 Panx3 NM_172454 6.0 Cdsn NM_001008424 5.5 
Tmem176b NM_023056 3.2 Ptgis NM_008968 5.7 Ptgis NM_008968 5.1 
Tnnc2 NM_009394 2.8 Col10a1 NM_009925 5.5 Fam180a NM_173375 4.6 
Nupr1 NM_019738 2.6 Nupr1 NM_019738 5.0 Fam20a NM_153782 4.2 
Timp4 NM_080639 2.5 Scx NM_198885 5.0 Aldh1l2 NM_153543 4.1 
Akp2 NM_007431 2.5 Ramp1 NM_016894 4.8 Loxl4 NM_053083 4.0 
C1qtnf3 NM_030888 2.4 Fam180a NM_173375 4.7 Ibsp NM_008318 4.0 
Tnc NM_011607 2.3 Slc6a9 NM_008135 4.5 Gper NM_029771 4.0 
Sp7 NM_130458 2.3 Ddit3 NM_007837 4.4 Slc40a1 NM_016917 4.0 
Srpx2 NM_026838 2.2 Fabp3 NM_010174 4.3 Chac1 NM_026929 3.6 
Wif1 NM_011915 2.2 Fam20a NM_153782 4.2 Unc5b NM_029770.2 3.6 
Table 4. Genes displaying increased expression in control cells (Shlux) compared to Mef2c shRNA 
knock down (Sh3) cells at days 3, 10 and 19 during osteoblast differentiation. Fold indicates change 
in Shlux relative to Sh3. Analysis is based on fold change.  
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A
B C
F
m
D
G
E
 
 
 
25 
 
 
 
0
5
10
15
20
25
3 7
Days
M
E
F
2
c
 
T
r
a
n
s
c
r
i
p
t
 
L
e
v
e
l
s
Control
pMef2c
0
1000
2000
3000
3 7
Days
O
S
C
 
T
r
a
n
s
c
r
i
p
t
 
L
e
v
e
l
s
Control
pMef2c
0
1000
2000
3000
3 7
Days
I
B
S
P
 
T
r
a
n
s
c
r
i
p
t
 
L
e
v
e
l
s
Control
pMef2c
0
0.1
0.2
0.3
0.4
9 16
Days
E
C
M
 
M
i
n
e
r
a
l
i
z
a
t
i
o
n
Control
pMef2c
A B C D
Figure 6 Stephens et al.
 
26 
 
27 
 
 
0
40
80
120
160
200
0 4 8 12 16
Days
A
L
P
 
a
c
t
i
v
i
t
y
Shlux
Sh1
Sh2
Sh3
0.0
0.4
0.8
1.2
1.6
2.0
6 9 12 15 18 21
Days
E
C
M
 
M
i
n
e
r
a
l
i
z
a
t
i
o
n
Shlux
Sh1
Sh2
Sh3
0.00
0.02
0.04
0.06
0.08
0.10
0 3 7 10 13
Days
M
E
F
2
c
 
T
r
a
n
s
c
r
i
p
t
 
L
e
v
e
l
s
Shlux
Sh1
Sh2
Sh3
A
C D
0.0
0.5
1.0
1.5
2.0
2.5
1 3 5 7Days
P
r
o
l
i
f
e
r
a
t
i
o
n
 
(
A
b
s
 
5
7
0
 
n
m
) Shlux
Sh 1
Sh 2
Sh 3
E
B
Figure 7 Stephens et al.
Days       7       10       13       17      19       21
Figure 8 Stephens et al.
0
500
1000
1500
2000
2500
0 2 4 6 8 10 12 14
IB
SP
 T
ra
ns
cr
ip
t L
ev
el
s Shlux
Sh1
Sh2
Sh3
0
1000
2000
3000
4000
5000
0 2 4 6 8 10 12 14
O
SC
 T
ra
ns
cr
ip
t L
ev
el
s Shlux
Sh1
Sh2
Sh3
0
50
100
150
200
0 2 4 6 8 10 12 14 16
M
M
P1
3 
Tr
an
sc
ri
pt
 L
ev
el
s Shlux
Sh3
0
20
40
60
80
100
0 2 4 6 8 10 12 14 16
D
PT
 T
ra
ns
cr
ip
t L
ev
el
s
Shlux
Sh3
0
4
8
12
16
20
0 2 4 6 8 10 12 14
O
SX
 T
ra
ns
cr
ip
t L
ev
el
s Shlux
Sh3
0
10
20
30
40
0 2 4 6 8 10 12 14
R
U
N
X2
 T
ra
ns
cr
ip
t L
ev
el
s Shlux
Sh3
A B
C D
E F
Days Days
Days Days
Days Days
 
 
 
 
 
 
28 
 
0500
1000
1500
2000
2500
3000
Day3 Day10 Day19
M
E
F
2
c
 
T
r
a
n
s
c
r
i
p
t
 
L
e
v
e
l
s
Shlux
Sh3
0
4000
8000
12000
16000
20000
Day3 Day10 Day19
I
B
S
P
 
T
r
a
n
s
c
r
i
p
t
 
L
e
v
e
l
s
Shlux
Sh3
80
90
100
110
120
130
140
150
160
Day3 Day10 Day19
R
U
N
X
2
 
T
r
a
n
s
c
r
i
p
t
 
L
e
v
e
l
s
Shlux
Sh3
0
1000
2000
3000
4000
5000
Day3 Day10 Day19
O
S
X
 
T
r
a
n
s
c
r
i
p
t
 
L
e
v
e
l
s
Shlux
Sh3
0
500
1000
1500
2000
2500
3000
3500
Day3 Day10 Day19
P
T
H
R
1
 
T
r
a
n
s
c
r
i
p
t
 
L
e
v
e
l
s
Shlux
Sh3
0
500
1000
1500
2000
2500
3000
3500
4000
4500
Day3 Day10 Day19
C
O
L
2
A
1
 
T
r
a
n
s
c
r
i
p
t
 
L
e
v
e
l
s
Shlux
Sh3
0
4000
8000
12000
16000
20000
Day3 Day10 Day19
B
g
l
a
p
-
r
s
1
 
T
r
a
n
s
c
r
i
p
t
 
L
e
v
e
l
s
Shlux
Sh3
0
4000
8000
12000
16000
20000
Day3 Day10 Day19
O
S
C
 
(
B
g
l
a
p
1
)
 
T
r
a
n
s
c
r
i
p
t
 
L
e
v
e
l
s Shlux
Sh3
A B C D
E F G H
Figure 9 Stephens et al.
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